ELZONRIS is the first and only approved treatment for BPDCN, a deadly hematologic cancer.1,2
Efficacy measures for previously-treated patients1,3
Efficacy measures | Previously-treated patients | (n=15)
---|---|
CR/CRc rate, % (n) | 13% (2) |
Median duration of CR/CRc, months Min, max |
Not yet reached 3.7, 13.9 |
ORR, % (n) | 67% (10) |
Bridge to stem cell transplantation, % (n) |
7% (1) |
*CRc = clinical complete response; defined as complete response with residual skin abnormality not indicative of active disease.1
BPDCN = blastic plasmacytoid dendritic cell neoplasm; CR = complete response; ORR = overall response rate.
Explore the baseline characteristics of previously-treated patients in the study
Key baseline demographics in the study reflect the patient population and variable presentation of BPDCN.1,3,4
Baseline characteristics: Previously-treated patients1,3,4
Characteristics | Previously-treated patients | (n=15)
---|---|
Male, % (n) | 86.7% (13) |
Female, % (n) | 13.3% (2) |
Median age | (min, max)72 (44, 80) |
ECOG PS, % (n) | |
0 | 33.3% (5) |
1 | 66.7% (10) |
BPDCN, % (n) | |
Skin | 86.7% (13) |
Bone marrow | 60.0% (9) |
Peripheral blood | 6.7% (1) |
Lymph nodes | 53.3% (8) |
Viscera | 26.7% (4) |
Prior treatments, % (n) | |
Radiation therapy | 33.3% (5) |
Stem cell transplantation | 26.7% (4) |
ECOG PS = Eastern Cooperative Oncology Group performance status.
Previous lines of therapy1,3,4
Number of lines | Previously-treated patients, % (n) |
---|---|
1 | 60% (9) |
2-3 | 27% (4) |
≥ 4 | 13% (2) |
- References:
- ELZONRIS [prescribing information]. New York, NY, US: Stemline Therapeutics, Inc.; December 2018.
- Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
- Data on file. Stemline Therapeutics, Inc.
- Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.